Adam is currently Senior Director of Process Development at Carisma Therapeutics, overseeing teams developing viral vector and cell product platforms producing a novel first in human CAR macrophage therapeutic for treatment of solid tumors. With over 14 years of industry experience, he serves as a technical subject matter expert responsible for authoring regulatory documents and collaborating with internal and external manufacturing, process, and analytical partners to drive key CMC initiatives. He previously worked as Associate Director of PD at WuXi Advanced Therapies as the upstream PD head and CMC team lead, leading technical evaluations of new projects across cell therapy, gene therapy, and viral vector modalities for contract manufacturing and development. His career started in PD at Merck Sharp & Dohme supporting Keytruda global CMC upstream technology transfer and regulatory filings and development of Rotateq live viral vaccine process and potency assay optimization initiatives. He was raised in Kentucky and has bachelor’s and master’s degrees in chemical engineering from the J.B. Speed School of Engineering at the University of Louisville.
